Implementation and outcomes of a severe acute respiratory coronavirus virus 2 (SARS-CoV-2) monoclonal antibody treatment program at an academic medical center serving a high-risk patient population

Abstract

Implementation and outcomes of a severe acute respiratory coronavirus virus 2 (SARS-CoV-2) monoclonal antibody treatment program at an academic medical center serving a high-risk patient population.

Feasibility and impact of a monoclonal antibody infusion program in reaching vulnerable underserved communities

“…3 A facility in our ZIP code reported that 78% of mAbs were used in BIPOC patients, comparable to our institution's 85%. 6 Thus, facilities located within BIPOC communities may be important in closing this gap, and existing relationships with these facilities, along with higher trust and accessibility, may play a role. Equitable access to medications and immunizations is important for current and future pandemics.…”